{"title":"年度最佳进展：卵巢癌","authors":"M. Lumish, Elise C. Kohn, William P. Tew","doi":"10.1097/01.ogx.0001016696.16905.e0","DOIUrl":null,"url":null,"abstract":"(Abstracted from Cancer 2024;130:837–845\n Although novel systemic therapies have prolonged survival in ovarian cancer, it remains the fifth leading cause of cancer-related death in women. In 2022, data showing an overall survival (OS) benefit from poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) were published after a 7-year follow-up period.","PeriodicalId":509854,"journal":{"name":"Obstetrical & Gynecological Survey","volume":"509 17","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Top Advances of the Year: Ovarian Cancer\",\"authors\":\"M. Lumish, Elise C. Kohn, William P. Tew\",\"doi\":\"10.1097/01.ogx.0001016696.16905.e0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"(Abstracted from Cancer 2024;130:837–845\\n Although novel systemic therapies have prolonged survival in ovarian cancer, it remains the fifth leading cause of cancer-related death in women. In 2022, data showing an overall survival (OS) benefit from poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) were published after a 7-year follow-up period.\",\"PeriodicalId\":509854,\"journal\":{\"name\":\"Obstetrical & Gynecological Survey\",\"volume\":\"509 17\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrical & Gynecological Survey\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.ogx.0001016696.16905.e0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.ogx.0001016696.16905.e0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
(Abstracted from Cancer 2024;130:837–845
Although novel systemic therapies have prolonged survival in ovarian cancer, it remains the fifth leading cause of cancer-related death in women. In 2022, data showing an overall survival (OS) benefit from poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) were published after a 7-year follow-up period.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
